Lannett (LCI) reported earnings on Tue 27 Aug 19 (a/h)

** charts after earnings **

 

Lannett beats by $0.16, beats on revs; guides FY20 revs above consensus

Reports Q4 (Jun) earnings of $0.37 per share, excluding non-recurring items, $0.16 better thanthe S&P Capital IQ Consensus of $0.21; revenues fell 21.7% year/year to $133.8 mln vs the $120.28 mln S&P Capital IQ Consensus. 

"Financial results for our fiscal 2019 fourth quarter, the first full quarter of the fiscal year without sales of Levothyroxine, exceeded or were at the upper end of our expectations. The quarter did benefit from a few items that were related to timing. Looking ahead, we expect to launch a number of new products that will continue to build our business in the near term and have begun adding products to our pipeline that have significant potential in the medium term and beyond."

Co issues upside guidancefor FY20, sees FY20 revs of $525-545 mln vs. $491.95 mln S&P Capital IQ Consensus; adj. EBITDA $145-160 mln

** 10 days later  **